跳转至内容
Merck
CN

475846

MIF Antagonist III, 4-IPP

别名:

MIF Antagonist III, 4-IPP, Macrophage Migration Inhibitory Factor Antagonist III, 4-IPP, 4-Iodo-6-phenylpyrimidine

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C10H7IN2
化学文摘社编号:
分子量:
282.08
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

Ic1ncnc(c1)c2ccccc2

InChI

1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H

InChI key

ZTCJXHNJVLUUMR-UHFFFAOYSA-N

assay

≥90% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

amber

solubility

DMSO: 50 mg/mL

shipped in

ambient

Quality Level

General description

A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC50 ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.

Packaging

Packaged under inert gas

Other Notes

Winner, M., et al. 2008. Cancer Res.68, 7253.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

存储类别

11 - Combustible Solids

wgk

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ricardo A de Azevedo et al.
Oncoimmunology, 9(1), 1846915-1846915 (2020-12-22)
Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持